Bactiguard and MAQUET Critical Care AB (MAQUET), a division of the Getinge Group, enter a collaboration to develop Bactiguard®-coated catheters for patients in intensive care.
Bactiguard’s strategy includes expanding its licensing business. MAQUET’s intention is to expand its portfolio of advanced monitoring solutions. Therefore, the companies have signed a letter of intent to develop Bactiguard® coated catheters, which prevent hospital acquired infections, for use in intensive care. A pre-study phase has been initiated, with the aim of entering a development and supply agreement for the global market.
“We are very proud and excited about the partnership with MAQUET and the Getinge Group. It has potential to expand our licensing business both geographically and by adding new devices”, says Johan Rugfelt, CEO Bactiguard.
“MAQUET is a leading global provider of medical systems. By applying the Bactiguard coating to MAQUET’s products, together we can prevent hospital acquired infections. Such infections are critical for patients in intensive care, and one of the greatest challenges in our time”, Johan Rugfelt continues.
Several years ago, a strategic partnership and licensing agreement with CR Bard, Inc (Bard) in the US was initiated. Since then, Bactiguard coated Foley-catheters have become market leading in the US and Japan. Bactiguard’s strategy is to expand the licensing business by adding new agreements to the current successful agreement with Bard.
Bactiguard Holding AB (publ) is required to disclose the above information under the provisions of the Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8:00 AM CET on 2 June 2014.
For more information, please contact:
Johan Rugfelt – CEO
johan.rugfelt@bactiguard.se
+46 708 724 739
Cecilia Edström – Director of Communications
cecilia.edstrom@bactiguard.se
+46 722 262 328
